Pioneering Research from Oregon's Legal Framework to Debut at Psych Congress 2025

Bendable Therapy and Osmind will unveil the first real-world evidence study of legal psilocybin services in the United States, advancing scientific insights into safety and effectiveness of psychedelic medicine. These preliminary findings, which will be presented at Psych Congress 2025, represents the first systematic collection and analysis of outcomes data from Oregon's supervised psilocybin program under state Measure 109. The study fills a critical evidence gap, especially as multiple groups advance psychedelics programs towards FDA approval and medical adoption.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916874550/en/

“This represents a pivotal moment for psychedelic research and policy,” said Amanda Gow, Executive Director at Bendable Therapy. “While Oregon’s program has served thousands of participants over nearly three years, there has been virtually no data on real-world outcomes—especially for the populations that clinical trials often exclude. Through Bendable Therapy and Osmind, we have systematically collected and analyzed data from our participants, providing the first evidence of how psilocybin services perform in a real-world setting. Our findings offer important insights into the safety and therapeutic potential of Oregon’s regulated model, informing other states as they consider similar programs.”

This study provides essential initial insights into who accesses these services and for which mental health conditions. These findings lay the foundation for future research to advance our understanding of psilocybin therapy, including its underlying mechanisms, individual response patterns, and long-term outcomes, which are critical to the healthcare system as a potential FDA-approved medical treatment.

“While clinical trials have shown psilocybin's therapeutic potential, this study provides the first naturalistic evidence from legal real-world settings within the U.S.,” said Jimmy Qian, President and Co-founder of Osmind. “It is critical that we learn from what is happening around us. This is an important opportunity to generate as much real-world evidence as possible so that psychedelics, if and when FDA-approved, can be responsibly and efficiently integrated into the US healthcare system. At Osmind, our goal is to use data, technology, and research to help as many people as possible benefit from innovative FDA-approved treatments.”

The IRB-approved study collected demographic data, mental health histories, open-ended reflections, validated clinical scales (PHQ-8, GAD-7, WHO-5), and psychedelic-specific measures. The study protocol was developed by Osmind and Bendable in collaboration with coauthor and renowned psychedelics researcher Robin Carhart-Harris, the Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco. This study was funded in part by The Jurvetson Foundation.

The following posters will be presented at Psych Congress 2025 in San Diego on September 19-20, 2025:

• "Real-world Evidence from Facilitated Psilocybin Sessions within Oregon's Legal Framework: Demographics, Engagement, and Motivations"
• "Real-world Outcomes of Facilitated Psilocybin Sessions under Oregon's Legal Framework"

Authors on the posters include: Jennie Davis, Amanda Gow, Ryan Reid (Bendable Therapy); Emily Shih, Jimmy J. Qian, L. Alison McInnes, William M. Sauve, (Osmind); Robin Carhart-Harris (UCSF). The research team is additionally preparing multiple manuscripts for peer review.

About Bendable Therapy

Bendable Therapy was founded by Amanda Gow and Ryan Reid with a clear mission: to help Oregon’s groundbreaking legal psychedelics program succeed by ensuring that this powerful therapy is safe, effective, and accessible.

About Osmind

Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s psychiatry-tailored software and services, used by leading psychiatry practices across the U.S., help improve patient outcomes while driving practice success. Osmind's network of over 800 clinics comprises the country's largest network of interventional psychiatry practices. Simultaneously, Osmind's clinic network, point-of-care software, and real-world data support life sciences companies in developing and scaling access to cutting-edge treatments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250916874550/en/

“While clinical trials have shown psilocybin's therapeutic potential, this study provides the first naturalistic evidence from legal real-world settings within the U.S.,” said Jimmy Qian, President and Co-founder of Osmind